CRISPR And Cas Gene Market 2024 - By Size, Share, Industry Growth Analysis Report By 2033

The new report published by The Business Research Company, titled ""CRISPR And Cas Gene Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the crispr and cas gene market size has grown exponentially in recent years. It will grow from $3.28 billion in 2023 to $3.97 billion in 2024 at a compound annual growth rate (CAGR) of 21.3%. The crispr and cas gene market size is expected to see exponential growth in the next few years. It will grow to $8.37 billion in 2028 at a compound annual growth rate (CAGR) of 20.5%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=13632&type=smp

Personalized Therapy Driving Surge In CRISPR And Cas Gene Market Growth
A growing focus on personalized therapy is expected to propel the growth of the CRISPR and Cas gene markets going forward. Personalized therapy refers to a medical model that uses an individual's genetic profile to guide decisions made concerning the diagnosis, treatment, and prevention of disease. CRISPR and the Cas gene, particularly Cas9, are used in personalized medicine, enabling precise modifications to an individual's genetic material and holding promise for breakthroughs in developing tailored therapies for genetic disorders, cancer, and various medical conditions. For instance, in January 2023, according to the Personalized Medicine Coalition, a US-based professional membership organization, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs) in 2022. Out of the 35 therapeutic NMEs, approximately 34%, which amounts to 12 of them, are classified as personalized medicines by the Personalized Medicine Coalition (PMC). Therefore, the rising demand for personalized therapy will drive the growth of the CRISPR and Cas gene markets.

CRISPR-Based Cell-Based Gene Therapy Revolutionizes Treatment Landscape In The CRISPR And Cas Gene Market
Major companies operating in the CRISPR and Cas gene markets are developing innovative products such as CRISPR-based cell-based gene therapy to enhance product offerings and gain a competitive advantage. CRISPR-based cell-based gene therapy involves using the CRISPR gene-editing technology to modify or correct genetic material within cells, offering a targeted and potentially revolutionary approach to treating genetic disorders, diseases, and other medical conditions at the cellular level. For instance, in December 2023, Vertex Pharmaceuticals Incorporated, a US-based biopharmaceutical company, received approval for CASGEVY (exagamglogene autotemcel [exa-cel]) from the U.S. Food and Drug Administration (FDA). CASGEVY is a CRISPR/Cas9 genome-edited gene therapy for the management of sickle cell disease (SCD) in individuals aged 12 and above who have recurrent vaso-occlusive crises. CASGEVY is a first-of-its-kind medication that has the potential to be a one-time transformational therapy for qualified sickle cell patients. CASGEVY administration necessitates specific training in stem cell transplantation, hence, Vertex is collaborating with experienced institutions to create a network of independently owned, approved treatment centers (ATCs) across the United States to provide CASGEVY to patients.

The crispr and cas gene market covered in this report is segmented -

1) By Product Type: Kits And Enzymes, Libraries, Design Tool, Antibodies, Other Products Types
2) By Service Type: Cell Line Engineering, gRNA Design, Microbial Gene Editing, DNA Synthesis
3) By Application: Clinical, Financial, Operational And Administrative
4) By End Use: Biotechnology And Pharmaceutical Companies, Academics And Government Research Institutes, Contract Research Organizations (CROs)

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=13632&type=discount

Major companies operating in the crispr and cas gene market report are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc, AstraZeneca plc., Danaher Corporation, Quest Diagnostics, Lonza Group AG, Bio-Rad Laboratories Inc., eGenesis, Novartis Institutes for BioMedical Research, Myriad Genetics Inc., GenScript, Takara Bio Inc., 23andMe Inc., Merck KGaA, Color Genomics Inc., Horizon Discovery Group Plc, Beam Therapeutics Inc, Intellia Therapeutics Inc., New England BioLabs, Recursion Pharmaceuticals Inc, Caribou Biosciences Inc., Cellectis S.A., Editas Medicine Inc.

Contents of the report:
1. Executive Summary
2. CRISPR And Cas Gene Market Report Structure
3. CRISPR And Cas Gene Market Trends And Strategies
4. CRISPR And Cas Gene Market - Macro Economic Scenario
5. CRISPR And Cas Gene Market Size And Growth
…..
27. CRISPR And Cas Gene Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/crispr-and-cas-gene-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.